Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
J Hepatol 79(6):15421556 Makri E, Goulas A, Polyzos SA (2021) Epidemiology, Pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease
These drugs are gaining attention not just for their efficacy in controlling blood sugar levels, but also for their unexpected benefits in weight loss
By the end of this article, you will feel confident in your ability to manage your treatment at home
For example, the total discontinuation rates were 27% in the SUSTAIN 6 trial of semaglutide (mean follow-up 39.8 months) and 42% in the REWIND trial of dulaglutide (median follow-up 65 months)
US$ 21.51
US$ 20.25
US$ 29.43
US$ 29.04
US$ 22.71
US$ 27.91
US$ 25.48
US$ 26.15
US$ 21.86
